Interobserver Variability in the Assessment of Tumor Budding in pT 3/4 Colon Cancer: Improvement by Supporting Immunohistochemistry?

colon cancer histology interobserver variability prognostic factor tumor budding

Journal

Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402

Informations de publication

Date de publication:
21 Sep 2020
Historique:
received: 15 08 2020
revised: 11 09 2020
accepted: 17 09 2020
entrez: 24 9 2020
pubmed: 25 9 2020
medline: 25 9 2020
Statut: epublish

Résumé

The prognostic significance of tumor budding in colon cancer is unequivocally documented, and the recommendations of the International Tumor Budding Consensus Conference (ITBCC) are currently the accepted basis for its assessment. Up to now, it is unknown whether the general use of a supporting cytokeratin immunohistochemistry can improve the interobserver variability and prognostic significance. Six investigators with different levels of experience reassessed 229 cases of colon carcinoma (pT3/4, N+/-, M0) with a supporting cytokeratin immunohistochemistry. The results were compared to previous assessments, which have been performed only on H & E. Bd3 was significantly associated with the occurrence of distant metastases according to the assessments of three out of six investigators (

Identifiants

pubmed: 32967382
pii: diagnostics10090730
doi: 10.3390/diagnostics10090730
pmc: PMC7555133
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : The study was supported by the Hermann-Egger Foundation with 3000 Euro. The Hermann-Egger Foundation is a social foundation, which supports mainly regional projects (incl. science) in Augsburg.
ID : -

Références

Anticancer Res. 2008 May-Jun;28(3B):1831-6
pubmed: 18630467
Histopathology. 2019 Jun;74(7):1005-1013
pubmed: 30698857
Histopathology. 2018 Nov;73(5):864-868
pubmed: 29956372
Virchows Arch. 2018 Aug;473(2):189-197
pubmed: 29626253
Histopathology. 2019 Oct;75(4):517-525
pubmed: 31081121
Pathol Res Pract. 2018 Sep;214(9):1273-1281
pubmed: 30017334
Dis Colon Rectum. 2016 May;59(5):396-402
pubmed: 27050601
Mod Pathol. 2012 Oct;25(10):1315-25
pubmed: 22790014
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Mod Pathol. 2019 May;32(5):675-683
pubmed: 30552417
Cancer Immunol Res. 2019 Apr;7(4):609-620
pubmed: 30846441
J Med Syst. 2019 Dec 18;44(2):38
pubmed: 31853654
Mod Pathol. 2020 May;33(5):825-833
pubmed: 31844269
Pathol Int. 2016 Feb;66(2):75-82
pubmed: 26753834
Mod Pathol. 2017 Sep;30(9):1299-1311
pubmed: 28548122
Virchows Arch. 2015 May;466(5):485-93
pubmed: 25701480
J Clin Oncol. 2019 Aug 1;37(22):1886-1894
pubmed: 31180819
Arch Pathol Lab Med. 2018 Aug;142(8):952-957
pubmed: 30040461

Auteurs

Benedikt Martin (B)

Institute of Pathology and Molecular Diagnostics, University Medical Center Augsburg, 86156 Augsburg, Germany.

Patrick Mayr (P)

Institute of Pathology and Molecular Diagnostics, University Medical Center Augsburg, 86156 Augsburg, Germany.
Department of Hematology and Clinical Oncology, University Medical Center Augsburg, 86156 Augsburg, Germany.

Regina Ihringer (R)

Institute of Pathology and Molecular Diagnostics, University Medical Center Augsburg, 86156 Augsburg, Germany.

Eva-Maria Schäfer (EM)

Institute of Pathology and Molecular Diagnostics, University Medical Center Augsburg, 86156 Augsburg, Germany.

Elżbieta Jakubowicz (E)

Institute of Pathology and Molecular Diagnostics, University Medical Center Augsburg, 86156 Augsburg, Germany.

Matthias Anthuber (M)

Department of Visceral Surgery, University Medical Center Augsburg, 86156 Augsburg, Germany.

Gerhard Schenkirsch (G)

Tumor Data Management, University Medical Center Augsburg, 86156 Augsburg, Germany.

Tina Schaller (T)

Institute of Pathology and Molecular Diagnostics, University Medical Center Augsburg, 86156 Augsburg, Germany.

Bruno Märkl (B)

Institute of Pathology and Molecular Diagnostics, University Medical Center Augsburg, 86156 Augsburg, Germany.

Classifications MeSH